SCM
CYCN icon

Sarissa Capital Management’s Cyclerion Therapeutics CYCN Stock Holding History

Sarissa Capital Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-12,500
Closed -$2.86M – 13
2019
Q2 		$2.86M Buy
+12,500
New +$3.54M 0.36% 10

Other funds holding CYCN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Sarissa Capital Management's CYCN Position: Q3 2019 in Review

Sarissa Capital Management sold out of Cyclerion Therapeutics (CYCN) in Q3 2019, closing a stake of 12,500 shares — an estimated $2.86M sold.

Sarissa Capital Management first reported a position in CYCN in Q2 2019 and held it in 1 quarter. The position peaked at $2.86M in Q2 2019. 90 funds tracked by Wall St. Rank hold CYCN as of Q3 2019.

  • Sarissa Capital Management reported no remaining Cyclerion Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sarissa Capital Management sold 12,500 Cyclerion Therapeutics shares in Q3 2019, an estimated $2.86M.
  • Sarissa Capital Management first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 1 quarter.
  • Sarissa Capital Management's Cyclerion Therapeutics position peaked at $2.86M in Q2 2019.
  • 90 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2019.

Based on Sarissa Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.